Pure Bioscience (PURE) Stock Statistics & Valuation Metrics

Pure Bioscience has a market cap or net worth of $6.94M. The enterprise value is $13.60M.

Pure Bioscience has 111,856,476 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pure Bioscience’s return on equity (ROE) is 1.17 and return on invested capital (ROIC) is -3683.53%.

The current PE Ratio of Pure Bioscience is -2.66. Pure Bioscience’s PEG ratio is 0.17.

In the last 12 months, Pure Bioscience had revenue of 1.96M and earned -3.35M in profits. Earnings per share was -0.03.

In the last 12 months, operating cash flow was -2.25M and capital expenditures 0.00, giving a free cash flow of -2.25M billion.

Pure Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Pure Bioscience upcoming earnings date is Jun 12, 2025, TBA Not Confirmed.

Pure Bioscience as a current ratio of 1.10, with Debt / Equity ratio of -116.88%

In the past 12 months, Pure Bioscience has paid 0.00 in taxes.

Pure Bioscience EV to EBITDA ratio is -3.76, with an EV/FCF ratio of -4.52.

Pure Bioscience has $202.00K in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.77M billion.

Gross margin is 58.27%, with operating margin of -159.50%, and net profit margin of -170.66%.

The average price target for Pure Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―